Novocure FY2024 revenue $605M (+19%), Q4 net loss $65.9M; Optune Lua approved and launched; PANOVA-3 trial met endpoint

NovoCure Ltd

2024-FY EPS reported -$1.56 revenue$605,220,000

FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).
Q4 net loss $65.9M ($0.61/sh); adjusted EBITDA $2.6M; cash $959.9M.
Optune Lua received FDA approval Oct 2024 for metastatic NSCLC; 52 prescriptions by year-end.
Phase 3 PANOVA-3 trial met primary endpoint in unresectable locally advanced pancreatic cancer.
2025 outlook: low mid-single digit GBM growth; margins impacted by product launches.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.